JIN SEOK KIM

Associate Professor

Severance Hospital

South Korea

Research Interests

Explore related searches

Professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Jin Seok Kim is an Associate Professor at Severance Hospital in South Korea. His research areas include multiple myeloma, plasma cell disorders, and paroxysmal nocturnal hemoglobinuria, as evidenced by his recent publications. Dr. Kim has contributed to the understanding of various therapies and their applications in hematologic conditions through multicenter studies and expert consensus guidelines.

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (22)

Seung Min Hahn

Yonsei University College of Medicine

SOUTH KOREA

JIN SEOK KIM

Research Interests

Explore related searches

Contact this professor

About

Articles (22)

Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study

NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma

Imaging in plasma cell disorders—consensus recommendations of the Asian myeloma network bone imaging workgroup

Prevention and Management of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria in Asia: A Narrative Review

Long-Term Outcomes of COVID-19 and Risk Factors for Prolonged or Persistent COVID-19 in Lymphoma Patients: A Multicenter, Retrospective Cohort Study

Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

Poor Mobilization-Associated Factors in Autologous Hematopoietic Stem Cell Harvest

A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea

Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry

Monitoring and Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia in Asia: An Expert Consensus

Real‐world data for the use of emicizumab in haemophilia A patients with inhibitors – First nationwide report from Korea

The first successful eculizumab rescue therapy of a kidney transplant recipient with atypical hemolytic uremic syndrome in South Korea: a case report

DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation

Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea

Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myeloma

Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea

Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis

Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma

Safety, pharmacokinetics, and pharmacodynamics of a next‐generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients

Collaborators (22)

Seung Min Hahn

Soo Mee Bang

Je-Hwan Lee

Ola Landgren

Kihyun Kim

Doh Yu Hwang

Do Young Kim

Sangmin Ahn

Kyu Ha Huh

Yong Kyun Won

Ja Min Byun

Joon Sup Yeom

Yong Park

Hyunsoo Cho

Young Shil Park

Jong Wook Lee

yu ri kim

Soo-Jeong Kim

Deog-Yeon Jo

Sung‐Soo Yoon

Minsun Jung

Seung Hyeok Han

Make your next move.